Endothelial and inflammatory biomarker profile at diagnosis reflects clinical heterogeneity of juvenile dermatomyositis and is prognostic for response to treatment in two independent cohorts

ConclusionThis study confirms the heterogeneity of new ‐onset JDM using serum biomarkers. Patients with high galectin‐9, CXCL10, TNFR2 and galectin‐1 may respond suboptimally to conventional treatment, and may benefit from more intensive monitoring and/or treatment.

Source: Arthritis and Rheumatology - February 27, 2020 Category: Rheumatology Authors: Judith Wienke, Lauren M. Pachman, Gabrielle A. Morgan, Joo Guan Yeo, Maria C. Amoruso, Victoria Hans, Sylvia S.M. Kamphuis, Esther P.A.H. Hoppenreijs, Wineke Armbrust, J. Merlijn van den Berg, Petra C.E. Hissink Muller, Kyra A. Gelderman, Thas Tags: FULL LENGTH Source Type: research